AbbVie M&A Comments Not Read Through for HCV and Achillion (ACHN), Says Deutsche Bank
Tweet Send to a Friend
Deutsche Bank maintained a Buy rating on Achillion Pharmaceuticals (NASDAQ: ACHN) with a price target of $25. The stock declined ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
